生命科学资讯
生物技术与制药领域的最新动态
Pressure builds as back-and-forth between uniQure and FDA intensifies
Alltrna undergoes third layoff round before entering clinic, cutting 35% of jobs
第一三共与德国Gaia签署协议，销售高胆固醇数字疗法。
Daiichi Sankyo pens pact with Germany's Gaia to sell digital therapeutic for high cholesterol
风投公司将在盐湖城开设3万平方英尺生物科技孵化器
VC firm to open 30K-square-foot biotech incubator in Salt Lake City
BCI视网膜植入医疗科技公司Science完成2.3亿美元C轮融资。
BCI retinal implant medtech Science closes major $230M series C round
PepGen遭遇部分临床暂停，分析师归咎于“FDA人手不足”。
PepGen hit with partial clinical hold, analysts blame 'understaffed FDA'
Guardant推出结肠癌血液检测新方案
Guardant hits the road with colon cancer blood test
罗氏斥资4.8亿美元注入韩国生物制药产业，构建全球临床试验"生态系统"。
Roche pumps $480M into South Korea biopharma industry to establish global trial 'ecosystem'
辉瑞肿瘤研发战略：杰夫·莱戈斯谈速度、广度与创新组合
Pfizer's oncology R&D strategy: Jeff Legos on speed, breadth and novel combinations
英伟达携手Droplet Biosciences深化医疗科技与癌症研究布局
Nvidia dives deeper into medtech, cancer research with Droplet Biosciences
ARPA-H启动1.58亿美元计划，助力首款淋巴系统药物研发。
ARPA-H launches $158M effort to aid first-ever lymphatic system medicines
拜耳放弃2亿美元收购AskBio中的一项庞贝病基因疗法，专注替代方案。
Bayer tosses 1 Pompe gene therapy from $2B AskBio buyout to focus on alternative option
英国投资6400万美元扩大临床试验覆盖至服务不足社区
UK invests $64M to expand clinical trial access to underserved communities
小野制药因战略考量放弃早期实体瘤药物研发。
Ono’s Deciphera drops early-stage solid tumor drug for strategic reasons
梯瓦制药与黑石集团达成4亿美元协议，资助与赛诺菲合作的IBD药物。
Teva bags $400M deal with Blackstone to fund Sanofi-partnered IBD drug
赛诺菲与中生制药达成15亿美元全球许可协议，引进首创JAK/ROCK资产
Sanofi strikes $1.5B global licensing deal for Sino Biopharm's first-in-class JAK/ROCK asset
新发癌症病例促使协和麒麟终止晚期自身免疫性疾病项目
New cancer cases prompt Kyowa to discontinue late-stage autoimmune disease program
Theravance因罕见病三期试验失败裁员半数，终止所有研发工作。
Theravance halves headcount, ends all R&D work after phase 3 rare disease fail
FDA详述拒绝Regenxbio罕见病基因疗法的理由。
FDA details rationale for rejecting rare disease gene therapy from Regenxbio